Lhasa Limited shared knowledge shared progress

2021 Webinar - An overview of Effiris 2.1; An enhanced qualitative model suite for anticipating and mitigating adverse drug reactions – Slides and recording

pdf fileFowkes A; Rowell P;

Effiris delivers state-of-the-art secondary pharmacology models, where each model has had the opportunity to learn from the private data of all pharmaceutical collaborators. As a result, Effiris overcomes one of the main challenges facing model development in drug discovery - leveraging the breadth of available high-quality proprietary data.

The presenters for this Effiris webinar were Lhasa Limited Science Team Leader, Dr. Adrian Fowkes and Product Owner, Phil Rowell.

Adrian and Phil presented how Effiris can be used to enhance secondary pharmacology profiling through the use of federated QSAR models - which have been appropriately trained from multi-party data, including proprietary and public sources. The webinar also included a demonstration of the new features being delivered in this enhanced version of Effiris.


Additional Documents

© 2023 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).